Evidence map›Paper›PMID 37332045›Full record

ArticleExperimental & molecular medicine2023

piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination.

Wentao Zhang, Zongtai Zheng, Keyi Wang, Weipu Mao, Xue Li, Guangchun Wang, Yuanyuan Zhang, Jianhua Huang, Ning Zhang, Pengfei Wu and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental & molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Wentao Zhang *Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Zongtai Zheng *Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, P. R. China.
Keyi Wang *Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Weipu Mao *Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Xue LiDepartment of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China.
Guangchun WangDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Yuanyuan ZhangInstitute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA.
Jianhua HuangDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Ning ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Pengfei WuDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Ji LiuDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Haimin ZhangDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Jianping CheDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Bo PengDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China. pengbo6908@163.com.
Junhua ZhengState Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University, Shanghai, P. R. China. zhengjh0471@sina.com.
Wei LiDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China. weili06@tongji.edu.cn.
Xudong YaoDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China. yaoxudong1967@163.com.
Tongji University · CNShanghai Tenth People's Hospital · CNCapital Medical University · CNGuangdong Provincial People's Hospital · CNHarvard University · USState Key Laboratory of Oncogene and Related Genes · CNWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating studies have confirmed that PIWI-interacting RNAs (piRNAs) are considered epigenetic effectors in cancer. We performed piRNA microarray expression analysis on renal cell carcinoma (RCC) tumor tissues and paired normal tissues and performed a series of in vivo and in vitro experiments to explore piRNAs associated with RCC progression and investigate their functional mechanisms. We found that piR-1742 was highly expressed in RCC tumors and that patients with high piR-1742 expression had a poor prognosis. Inhibition of piR-1742 significantly reduced tumor growth in RCC xenograft and organoid models. Mechanistically, piRNA-1742 regulates the stability of USP8 mRNA by binding directly to hnRNPU, which acts as a deubiquitinating enzyme that inhibits the ubiquitination of MUC12 and promotes the development of malignant RCC. Subsequently, nanotherapeutic systems loaded with piRNA-1742 inhibitors were found to effectively inhibit the metastasis and growth of RCC in vivo. Therefore, this study highlights the functional importance of piRNA-related ubiquitination in RCC and demonstrates the development of a related nanotherapeutic system, possibly contributing to the development of therapeutic approaches for RCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsEndopeptidasesEndosomal Sorting Complexes Required for TransportHeterogeneous-Nuclear Ribonucleoprotein UHumansMucinsPiwi-Interacting RNARNA, Small InterferingUbiquitin ThiolesteraseEndopeptidasesEndosomal Sorting Complexes Required for TransportHeterogeneous-Nuclear Ribonucleoprotein UHNRNPU protein, humanMUC12 protein, humanMucinsPiwi-Interacting RNARNA, Small InterferingUbiquitin ThiolesteraseUSP8 protein, human

Identifiers

PMID37332045
PMCPMC10318070
OpenAlexW4381122221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.